A detailed history of Csm Advisors, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Csm Advisors, LLC holds 66,965 shares of GILD stock, worth $5.9 Million. This represents 0.32% of its overall portfolio holdings.

Number of Shares
66,965
Previous 68,275 1.92%
Holding current value
$5.9 Million
Previous $5 Million 8.14%
% of portfolio
0.32%
Previous 0.33%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$63.15 - $72.88 $82,726 - $95,472
-1,310 Reduced 1.92%
66,965 $4.6 Million
Q1 2024

May 15, 2024

SELL
$71.58 - $87.29 $96,633 - $117,841
-1,350 Reduced 1.94%
68,275 $5 Million
Q4 2023

Feb 14, 2024

SELL
$73.27 - $83.09 $72,903 - $82,674
-995 Reduced 1.41%
69,625 $5.64 Million
Q3 2023

Nov 13, 2023

SELL
$73.94 - $80.67 $221,450 - $241,606
-2,995 Reduced 4.07%
70,620 $5.29 Million
Q2 2023

Aug 14, 2023

SELL
$76.01 - $86.7 $87,411 - $99,705
-1,150 Reduced 1.54%
73,615 $5.67 Million
Q4 2022

Feb 14, 2023

SELL
$62.32 - $89.47 $122,147 - $175,361
-1,960 Reduced 2.55%
74,765 $6.42 Million
Q3 2022

Nov 14, 2022

SELL
$59.54 - $68.01 $1.21 Million - $1.38 Million
-20,255 Reduced 20.89%
76,725 $4.73 Million
Q2 2022

Aug 11, 2022

SELL
$57.72 - $65.01 $577 - $650
-10 Reduced 0.01%
96,980 $6 Million
Q1 2022

May 16, 2022

SELL
$57.92 - $72.58 $544,448 - $682,252
-9,400 Reduced 8.84%
96,990 $5.77 Million
Q4 2021

Feb 09, 2022

SELL
$64.88 - $73.64 $228,377 - $259,212
-3,520 Reduced 3.2%
106,390 $7.73 Million
Q2 2021

Aug 16, 2021

SELL
$63.47 - $69.35 $335,121 - $366,167
-5,280 Reduced 4.58%
109,910 $7.57 Million
Q1 2021

May 21, 2021

BUY
$60.0 - $68.46 $6.91 Million - $7.89 Million
115,190 New
115,190 $7.45 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $110B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Csm Advisors, LLC Portfolio

Follow Csm Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Csm Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Csm Advisors, LLC with notifications on news.